|
Affymax
Affymax is leading the way in creating novel approaches for improving patient care for serious and life-threatening conditions in kidney disease and cancer. We are building a pipeline of peptide drugs against clinically validated targets that demonstrate significant advantages over currently marketed protein products.
Our flagship drug candidate, Hematide™, is a next-generation erythropoiesis stimulating agent (ESA) that has been designed to stimulate the production of red blood cells for the treatment of anemia caused by chronic disease.
Contact information:
|
